Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 8Phase 1 7Phase 4 3Phase 1/2 3

Status

Completed 6Recruiting 1

Sponsor Class

OTHER 7INDUSTRY 7

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Genitourinary 2Other solid neoplasm 1

Conditions

Neoplasms 3Solid Cancer 1Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × cabazitaxel × Clear all
NCT05818683 2026-05-08

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT01447225 2016-09-14

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals

Phase 1 Completed
43 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01140607 2015-07-21

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Sanofi

Phase 1 Completed
56 enrolled
Tumor-Agnostic

Neoplasms

NCT01324583 2015-01-07

Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer

Sanofi

Phase 1 Completed
48 enrolled
Genitourinary

Prostatic Neoplasms

NCT00925743 2013-05-16

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Sanofi

Phase 1 Completed
76 enrolled

Solid Cancer

NCT01755390 2012-12-24

A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
42 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01087021 2011-12-16

QT-Cab

Sanofi

Phase 1 Completed
45 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡